12 Feb 2020

Alastair Smith provides overview of pre|CISION^TM prodrug technology and update on AVA6000 clinical trial

Investors | Therapeutics

04 Feb 2020

Alastair Smith provides update on AffyXell collaboration and licence agreement

Investors

28 Jan 2020

Alastair Smith provides update on TMAC programme

Investors | Therapeutics

28 Jan 2020

Successful initial proof-of-concept for a proprietary new class of anti-cancer therapy

Investors | Therapeutics

24 Jan 2020

Alastair Smith interview discussing trading update ended 31 December 2019

Investors

23 Jan 2020

Trading update

Investors

21 Jan 2020

Appointment of Non Executive Director

Investors

08 Jan 2020

Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture

Investors | News | Therapeutics

05 Dec 2019

Alastair Smith interview

Investors | News | Reagents & Diagnostics | Therapeutics

13 Nov 2019

LG Chem Life Sciences Expands Partnership with Avacta

Investors | Therapeutics